Table 3 Descriptive characteristics of the included study participants
From: Denosumab for treating periprosthetic osteolysis: a feasibility study
Denosumab | Placebo | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Mean | SD | N | % | Mean | SD | N | % | ||||
Age | 77 | 5 | 70 | 8 | |||||||
Sex | |||||||||||
Male | 3 | 60 | 4 | 80 | |||||||
Female | 2 | 40 | 1 | 20 | |||||||
Height (cm) | 172 | 12 | 178 | 10 | |||||||
Weight (kg) | 88 | 15 | 92 | 27 | |||||||
Time after surgery (years) | 22 | 19 | 4 | ||||||||
ASA | 1 | 0 | 0 | 2 | 40 | ||||||
2 | 5 | 100 | 0 | 0 | |||||||
3 | 0 | 0 | 3 | 60 | |||||||
Volume osteolysis (cm3) | 8.1 | 5.8 | 5.4 | 6.5 | |||||||